From: ISO 10993 biological evaluation of novel hemostatic powder – 4SEAL®
Negative control | Study group | |||
---|---|---|---|---|
Female | Male | Female | Male | |
Cell type response | ||||
Polymorphonuclear cells | 0 | 1 | 0 | 1 |
Lymphocytes | 1 | 3 | 1 | 1 |
Plasma cells | 0 | 1 | 0 | 0 |
Macrophages | 3 | 4 | 3 | 3 |
Giant cells | 1 | 2 | 0 | 1 |
Necrosis | 0 | 1 | 0 | 0 |
Subtotal (×2) | 10 | 24 | 8 | 12 |
Tissue response | ||||
Neovascularization | 3 | 2 | 3 | 3 |
Fibrosis | 1 | 3 | 1 | 2 |
Subcutaneous changes | 4 | 4 | 4 | 4 |
Fatty infiltrate | 2 | 2 | 0 | 2 |
Muscular layer infiltration | 3 | 2 | 0 | 3 |
Subtotal | 23 | 49 | 16 | 32 |
Total | 72 | 48 | ||
Average | 36 | 24 |